October 14, 2011 -- BeiGene, based in Beijing’s Zhongguancun Life Science Park, has acquired China rights to two clinical-stage compounds, both of them oncology drug candidates, from Janssen Pharmaceutica NV, a division of Johnson & Johnson. Founded last year, BeiGene has an ambitious two-pronged business plan that combines in-licensing of five clinical stage drug candidates with developing its own novel drugs. The two drug candidates, intetumumab and MTKi-327, are the first acquisitions the company has made. More details....
Stock Symbol: (NYSE: JNJ)
